טוען...
Comparison of futility monitoring guidelines using completed phase III oncology trials
BACKGROUND: Futility (inefficacy) interim monitoring is an important component in the conduct of phase III clinical trials, especially in life threatening diseases. Desirable futility monitoring guidelines allow timely stopping if the new therapy is harmful or if it is unlikely to demonstrate to be...
שמור ב:
| הוצא לאור ב: | Clin Trials |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5300958/ https://ncbi.nlm.nih.gov/pubmed/27590208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774516666502 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|